Compare · ABT vs DERM
ABT vs DERM
Side-by-side comparison of Abbott Laboratories (ABT) and Journey Medical Corporation (DERM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and DERM operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $153.59B, about 879.8x DERM ($174.6M).
- Over the past year, ABT is down 35.0% and DERM is down 7.1% - DERM leads by 27.9 points.
- ABT has been more active in the news (7 items in the past 4 weeks vs 1 for DERM).
- ABT has more recent analyst coverage (25 ratings vs 7 for DERM).
- Company
- Abbott Laboratories
- Journey Medical Corporation
- Price
- $88.09-1.73%
- $6.33+1.28%
- Market cap
- $153.59B
- $174.6M
- 1M return
- +5.08%
- +22.77%
- 1Y return
- -35.03%
- -7.11%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 7
- 1
- Recent ratings
- 25
- 7
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Journey Medical Corporation
Journey Medical Corporation develops and commercializes pharmaceutical products for the treatment of dermatological conditions. It markets generic prescription drugs for dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Latest ABT
- Abbott declares 410th consecutive quarterly dividend
- New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers
- New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
- SEC Form SD filed by Abbott Laboratories
- Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
- ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
- Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
- SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K
- SEC Form SCHEDULE 13G filed by Abbott Laboratories
- SEC Form 10-Q filed by Abbott Laboratories
Latest DERM
- Journey Medical Corporation to Participate in A.G.P.'s Annual Virtual Healthcare Conference
- SEC Form 10-Q filed by Journey Medical Corporation
- Journey Medical Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
- Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026
- SEC Form DEFA14A filed by Journey Medical Corporation
- SEC Form DEF 14A filed by Journey Medical Corporation
- Chief Operating Officer Alloush Ramsey was granted 46,863 shares, increasing direct ownership by 8% to 598,543 units (SEC Form 4)
- CFO Benesch Joseph was granted 28,907 shares, increasing direct ownership by 12% to 261,371 units (SEC Form 4)
- President & CEO Maraoui Claude was granted 49,277 shares, increasing direct ownership by 2% to 2,435,990 units (SEC Form 4)